Docoh
Loading...

NRXP NRX Pharmaceuticals

News

From Benzinga Pro
52 Biggest Movers From Yesterday
1 Dec 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
12 Health Care Stocks Moving In Tuesday's Intraday Session
30 Nov 21
Movers
Gainers
12 Health Care Stocks Moving In Tuesday's After-Market Session
30 Nov 21
Movers
Gainers Lannett (NYSE:LCI) shares rose 11.61% to $1.73 during Tuesday's after-market session. The market value of their outstanding shares is at $74.3 million.
35 Stocks Moving In Tuesday's Mid-Day Session
30 Nov 21
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers
51 Biggest Movers From Yesterday
30 Nov 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers
Mid-Afternoon Market Update: Dow Jumps 300 Points; Krystal Biotech Shares Spike Higher
29 Nov 21
Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets
Toward the end of trading Monday, the Dow traded up 0.87% to 35,204.42 while the NASDAQ climbed 1.96% to 15,795.08. The S&P also rose, gaining 1.55% to 4,665.67.
Mid-Day Market Update: Crude Oil Rises 4%; Fennec Pharmaceuticals Shares Slide
29 Nov 21
Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets
Midway through trading Monday, the Dow traded up 0.30% to 35,005.10 while the NASDAQ climbed 1.39% to 15,707.48. The S&P also rose, gaining 0.97% to 4,639.11.
33 Stocks Moving In Monday's Mid-Day Session
29 Nov 21
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers Krystal Biotech, Inc. (NASDAQ: KRYS) shares jumped 116.4% to $86.13 after the company announced positive topline results from the GEM-3 Phase 3 trial of investigational beremagene geperpavec (B-VEC, Vyjuvek) for dystrophic Epidermolysis Bullosa (dystrophic EB).
12 Health Care Stocks Moving In Monday's Pre-Market Session
29 Nov 21
Movers
Why Are NRx Pharma's Shares Soaring Premarket?
29 Nov 21
Biotech, Long Ideas, News, Health Care, Small Cap, Movers, Trading Ideas, General
NRx Pharmaceuticals (NASDAQ: NRXP) has completed an analysis in the subgroup of Zyesami and placebo-treated patients previously treated with Gilead Science Inc's (NASDAQ: GILD) remdesivir in the COVID
NRx Pharmaceuticals Identifies Significantly Higher Likelihood Of Surviving And Recovering From Critical COVID-19 In ZYESAMI Treated Patients Previously Administered Remdesivir
29 Nov 21
Biotech, News, General
Analysis was conducted in the subgroup of ZYESAMI- and placebo-treated patients who were previously treated with remdesivir in the COVID-AIV trial representing approximately 70 percent of the study
56 Biggest Movers From Friday
29 Nov 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers
12 Health Care Stocks Moving In Friday's Intraday Session
26 Nov 21
Intraday Update, Markets, Movers
NRx Pharma Skyrockets After BriLife COVID-19 Vaccine Data Against Delta Variant
26 Nov 21
Biotech, Long Ideas, News, Health Care, Small Cap, Movers, Trading Ideas, General
Israel Institute for Biological Research (IIBR) has posted scientific results from an initial sample of Phase 2 vaccinated patients to assess the BriLife vaccine against the COVID-19 Delta variant.
NRx Pharmaceuticals Notes New Data On BriLife COVID-19 Vaccine Effectiveness Against Delta Variant Posted By Israel Institute For Biological Research
26 Nov 21
News, FDA
NRx Pharmaceuticals (NASDAQ:
FDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate
24 Nov 21
Biotech, News, Penny Stocks, Health Care, FDA, Movers, Trading Ideas, General
Relief Therapeutics Holding SA's (OTC: RLFTF) collaborating partner NRx Pharmaceuticals Inc (NASDAQ: NRXP) has announced that the
20 Stocks Moving in Monday's Pre-Market Session
22 Nov 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Astra Space, Inc. (NASDAQ: ASTR) rose 39.6% to $13.30 in pre-market trading after declining around 3% on Friday. Astra Space recently reported a Q3 loss of $0.06 per share.
The Daily Biotech Pulse: Kezar Jumps On Data, Biogen R&D Chief To Retire, Molecular Partners Wilts On COVID Trial Disappointment
16 Nov 21
Biotech, Earnings, News, Penny Stocks, Offerings, Small Cap, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
NRX Pharmaceuticals Q3 EPS $(0.40) Down From $(0.15) YoY
16 Nov 21
Earnings, News
NRX Pharmaceuticals (NASDAQ:NRXP) reported quarterly losses of $(0.40) per share. This is a 166.67 percent decrease over losses of $(0.15) per share from the same period last year.
Earnings Scheduled For November 16, 2021
16 Nov 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Ozon Holdings (NASDAQ:OZON) is expected to report quarterly loss at $0.90 per share on revenue of $602.00 million.

Press releases

From Benzinga Pro
Thinking about buying stock in Naked Brand, NRX Pharmaceuticals, Biofrontera, Norwegian Cruise Line, or Twitter?
29 Nov 21
Opinion, Press Releases
NEW YORK, Nov. 29, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NAKD, NRXP, BFRI, NCLH, and TWTR.
NRx Pharmaceuticals Identifies Significantly Higher Likelihood of Surviving and Recovering from Critical COVID-19 in ZYESAMI® (aviptadil) Treated Patients Previously Administered Remdesivir
29 Nov 21
News, Press Releases
Analysis was conducted in the subgroup of ZYESAMI- and placebo-treated patients who were previously treated with remdesivir in the COVID-AIV trial representing approximately 70 percent of the study populationAnalysis was
NRx Pharmaceuticals Notes New Data on BriLife® COVID-19 Vaccine Effectiveness Against Delta Variant Posted by Israel Institute for Biological Research
26 Nov 21
Health Care, Press Releases, General
Analysis of Blood Samples from Patients who Responded to the BriLife® Vaccine During Phase 2 Trial Suggests that the Same Level of Response was Seen Against the Delta Variant as Against the Original "Wild-Type"
Relief Reports that its U.S. Collaboration Partner has Announced the U.S. Food and Drug Administration has Denied Breakthrough Designation for Aviptadil
24 Nov 21
News, Press Releases
Geneva, Switzerland, November 24, 2021 - RELIEF THERAPEUTICS Holding SA ((SIX: RLF, OTCQB:RLFTF, RLFTY)) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief from serious
NRx Pharmaceuticals Reports Third-Quarter 2021 Business Update and Financial Results
16 Nov 21
Earnings, Press Releases
RADNOR, Pa., Nov. 16, 2021 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NASDAQ:NRXP) (NRx), a clinical-stage, biopharmaceutical company, today provided a business update and financial results for the quarter ended
NRx Pharmaceutical's Chairman and Chief Executive Officer Jonathan Javitt to Present Company Business Update at H.C. Wainwright 7th Annual Israel Conference
12 Nov 21
News, Press Releases
RADNOR, Pa., Nov. 12, 2021 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage, biopharmaceutical company, today announced its Chairman of the Board and Chief Executive Officer, Jonathan Javitt,
Relief Reports that its U.S. Collaboration Partner has Announced it has Received a U.S. Food and Drug Administration Review of Aviptadil Manufacturing Information
12 Nov 21
Press Releases
GENEVA, SWITZERLAND / ACCESSWIRE / November 12, 2021 / RELIEF THERAPEUTICS Holding SA ((SIX:RLF, OTCQB:RLFTF) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief from
NRx Pharmaceuticals Receives US Food and Drug Administration Review of ZYESAMI® (aviptadil) Manufacturing Information
11 Nov 21
Health Care, Press Releases, General
US Food and Drug Administration Review Allows for High Volume Production of ZYESAMI® (aviptadil)Shelf Life of ZYESAMI Now Extended from 62 Days to 150 Days RADNOR, Pa., Nov. 11, 2021 (GLOBE NEWSWIRE) -- NRx
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NRx Pharmaceuticals, Inc. - NRXP
9 Nov 21
News, Legal, Press Releases
NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NRx Pharmaceuticals, Inc. ("NRx" or the "Company") (NASDAQ:NRXP). Such investors are advised to contact
NRx Pharmaceuticals to Report Third Quarter 2021 Financial and Business Update on Tuesday, November 16, 2021
9 Nov 21
News, Health Care, Press Releases
RADNOR, Pa., Nov. 09, 2021 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NRx) (NASDAQ:NRXP), a clinical-stage, global biopharmaceutical company, today announced that management will report third-quarter 2021 financial
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NRx Pharmaceuticals, Inc. - NRXP
8 Nov 21
Press Releases
New York, New York--(Newsfile Corp. - November 8, 2021) - Pomerantz LLP is investigating claims on behalf of investors of NRx Pharmaceuticals, Inc. ("NRx" or the "Company") (NASDAQ:NRXP). Such investors are advised to
NRx Pharmaceuticals Initiates Senior Level Finance and Business Initiatives with Luxembourg Ministry of the Economy, BNP Paribas, and Vaccine Manufacturing Partners for BriLife® COVID-19 Vaccine Production
5 Nov 21
Press Releases
RADNOR, Pa., Nov. 5, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NASDAQ: NRXP), via its subsidiary, NRx Luxembourg (NRx), has concluded a business mission to Luxembourg at the invitation of the Luxembourg Ministry of the
Relief Reports U.S. Collaboration Partner's Emergency Use Authorization Request for ZYESAMI/RLF-100 (aviptadil) for Patients with Critical COVID-19 with Respiratory Failure was Declined by U.S. FDA
5 Nov 21
News, Press Releases
GENEVA, SWITZERLAND / ACCESSWIRE / November 5, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic relief from serious
US Food and Drug Administration Declines Emergency Use Authorization for ZYESAMI® (aviptadil) for Patients with Critical COVID-19 with Respiratory Failure
4 Nov 21
Press Releases
RADNOR, Pa., Nov. 4, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company (NRx), today announced that the US Food and Drug Administration (FDA) has declined to issue an
Relief Reports U.S. Collaboration Partner has Announced Favorable New Safety Report for Aviptadil in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19
3 Nov 21
News, Press Releases
GENEVA, SWITZERLAND / ACCESSWIRE / November 3, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief from serious
NRx Pharmaceuticals Announces Favorable, New Safety Report for ZYESAMI® (aviptadil) in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19
2 Nov 21
Press Releases
RADNOR, Pa., Nov. 2, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NASDAQ:NRXP), a clinical-stage, biopharmaceutical company, today provided a new safety update on ZYESAMI® (aviptadil), which is being tested in the
Thinking about buying stock in Plug Power, Cemtrex, Ocugen, NRX Pharmaceuticals, or FuelCell Energy?
15 Oct 21
Opinion, Press Releases
NEW YORK, Oct. 15, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PLUG, CETX, OCGN, NRXP, and FCEL.
Relief Reports U.S. Collaboration Partner Announces Journal of Infectious Diseases and Treatment Publishes Positive Aviptadil Data in High Comorbidity Critical COVID-19 Patients w/ Respiratory Failure
15 Oct 21
Press Releases
GENEVA, SWITZERLAND / ACCESSWIRE / October 15, 2021 / RELIEF THERAPEUTICS Holding SA ((SIX:RLF, OTCQB:RLFTF) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief from serious
Thinking about buying stock in NRX Pharmaceuticals, Teligent, BioXcel Therapeutics, FuelCell Energy, or United States Steel?
14 Oct 21
Opinion, Press Releases
NEW YORK, Oct. 14, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NRXP, TLGT, BTAI, FCEL, and X.
Journal of Infectious Diseases and Treatment Publishes Positive Trial Data of Aviptadil in High Comorbidity Patients Suffering from Critical COVID-19 with Respiratory Failure
14 Oct 21
Press Releases
RADNOR, Pa., Oct. 14, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NASDAQ:NRXP), today announced the publication of peer-reviewed results from a prospective, open-label, administratively controlled trial of aviptadil for